Video
Dr. Leslie on the 3-Year Follow-Up of the ZUMA-5 Trial in R/R iNHL
Author(s):
In Partnership With:
Lori A. Leslie, MD, discusses the 3-year follow-up data of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Lori A. Leslie, MD, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, discusses the 3-year follow-up data of the phase 2 ZUMA-5 trial (NCT03105336) in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL).
The phase 2 trial is evaluating patients with relapsed/refractory iNHL who are treated with the CAR T-cell therapy, axicabtagene ciloleucel (axi-cel; Yescarta).
Based on previous data, it appears that axi-cel is a durable option for patients with relapsed or refractory indolent lymphoma, Leslie notes. The 3-year progression-free survival rate was 65% and the 3-year lymphoma-specific survival rate was 89%, indicating that patients can have durable responses following a single CAR T infusion, Leslie says.
Additionally, more patients with marginal zone lymphoma are being observed, and their overall survival has improved, Leslie continues. Although axi-cel is not yet FDA approved for patients with marginal zone lymphoma, the NCCN has recommended axi-cel for patients who have received 2 or more prior lines of therapy, Leslie concludes.
